secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2026-06-30T12:05:11+00:00
Accession:  0001517022-26-000047
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VOICE trial interim analysis shows Vafseo superior to ESA on composite endpoint; trial stopped
--------------------------------------------------------------------------------

- Win odds 1.16 (95% CI 1.06-1.28, p=0.0016) for all-cause mortality/hospitalization composite.
- Hospitalizations per patient-year: 1.11 (Vafseo) vs 1.23 (ESA); incidence rate ratio 0.90 (p<0.05).
- Mortality rates similar: 8.77% vs 8.78% per 100 patient-years; rate ratio 1.00 (CI 0.718-1.391).
- Trial stopped on recommendation of Independent Data Monitoring Committee and Trial Steering Committee.
- Results replicate safety findings from INNO2VATE phase 3 program; data to be submitted for scientific meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000047/0001517022-26-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000047/akba-20260630.htm
  HTML page:      https://secwatch.observer/filing/0001517022-26-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer